131 Table 1 Baseline characteristics SFNSL >11 Group size (n) 36 Sex (male), % (n) 58 (21) Ethnicity (caucasian), % (n) 94 (34) Age (mean years, ±sd) 57 (±10) Patients with suspected SFN by neurologist, % (n) 19 (7) Duration of sarcoidosis symptoms (years, ±sd) 15 (±4) Duration of neurologic symptoms (years, ±sd) 9 (±3) Duration of neurologic symptoms in suspected SFN (years, ±sd) 10 (±5) Sarcoidosis diagnosis with biopsy, % (n) 83 (26) Other risk factors for SFN, % (n) Diabetes Mellitus Hypothyroidism Fibromyalgia Vitamin B12 deficiency Trauma 17 (6) 6 (2) 6 (2) 3 (1) 3 (1) Smoking status, % (n) Never 44 (16) Current 0 (0) Former 39 (14) Unknown 17 (6) Scadding stage, % (n) stage 0 8 (3) stage 1 31 (11) stage 2 17 (6) stage 3 8 (3) stage 4 36 (13) Main treatment indication, % (n) Pulmonary 44 (16) Cardiac 14 (5) Neurologic Manifestations 11 (4) Other 30 (11) Medication use during Inflximab, % (n) Corticosteroids 69 (25) Methotrexate 83 (30) Azathioprine 14 (5) Hydroxychloroquine 8 (3) Deceased, % (n) 11 (4) In our study cohort, inflammatory activity defined by SUVmax improved with a mean of -3.7 (p=<0.001) during treatment, see Figure 2.A. When comparing SFNSL-scores at the start and the end of treatment, a difference in the mean of -1.9 points was found (p = 0.446), see Figure 2B. The change of SFNSL-score seems not to correlate with the change in sarcoidosis activity measured by FDG-PET, as can be seen in figure 3. Only half of the population showed a decrease of more than 3.5 points on the SFNSL questionnaire. 8 137 8
RkJQdWJsaXNoZXIy MjY0ODMw